异动解读 | Aktis Oncology盘中大涨50%,IPO定价及礼来认购提振股价

异动解读
Jan 10

Aktis Oncology(AKTS)今日盘中大涨50%,引起了市场的广泛关注。

消息面上,该公司今晚将在纳斯达克上市,通过发行1770万股股票,每股定价18美元,募集了3.18亿美元。礼来(LLY)已表示将认购价值1亿美元的股票,这一重大投资显著提升了市场对Aktis Oncology的信心。

Aktis Oncology是一家临床阶段的肿瘤学公司,专注于开发针对常见实体瘤的α粒子放射性药物。其研发管线包括针对Nectin-4表达癌症的Ac-AKY-1189和针对B7-H3表达肿瘤的Ac-AKY-2519,预计将在未来几年取得重要进展。此外,公司还管理着多个同位素供应合作伙伴关系,并计划在2026年投入运营内部cGMP设施。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10